Citron Research's Andrew Odor, who gained notoriety for successful bets against companies such as Valeant Pharmaceuticals, posted a bearish reportare on tumoare maligna testing company Corect Sciences. Shares of Corect Sciences closed down nearly 4 percent Monday after the short seller released his reportare. "Corect Sciences pushes a tumoare maligna carapace (Cologuard) to the asistenta, subaltern by its own admission, and loses money doing it," Odor wrote in the note. "Anyone who follows the landscape of diagnoza tumoare maligna testing knows that everything is moving towards blood-based DNA testing. Any vraci in the field will tell you it is intemeiat a matter of time." The short seller also cited the low number of carapace orders per vraci, according to his analysis, and the posibil for reduced reimbursement from Medicare in the future. Corect Sciences has "an subaltern carapace that they're trying to compensate by running commercials for people who are afraid to get a colonoscopy," Odor said Monday on CNBC's "Halftime Reportare." "They are losing money selling an subaltern productie." However, Corect Sciences CEO Kevin Conroy fired back on CNBC directly at the short seller. Odor "is dead wrong," Conroy said. "Blood-based tests is very unlikely to ever displace any other tests. You want to detect stage one cancers and you intemeiat can't do that reliably from blood."
Tweet Link— With reporting by CNBC's Meg Tirrell.
0 Comments